NCT03550391
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Radiation therapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have 5+ brain metastases
Exclusions: Patients with widespread definitive leptomeningeal metastasis; Prior cranial radiation therapy
https://ClinicalTrials.gov/show/NCT03550391